RBCC Increases Focus on Parkinson's Disease
NOKOMIS, Fla.--(BUSINESS WIRE)-- As Rainbow Coral Corp. (OTCBB: RBCC) nears the completion of a ground-breaking joint venture agreement with Amarantus BioSciences (OTCBB: AMBS), the market demand for a cure to Parkinson's disease grows stronger by the day.
Researchers believe that Parkinson's is caused by the destruction of cells in various parts of the brain, including the substantia nigra, where dopamine is produced. Without dopamine, the brain can't properly transmit signals that allow for coordinated movement. The Parkinson's Disease Foundation estimates that as many as one million Americans suffer from Parkinson's disease, and 60,000 new patients are diagnosed each year.
Parkinson's typically occurs in older people, and as the world's population ages, incidence of the disease is on the rise. To battle Parkinson's, more than 150 drugs are currently in the pipeline around the world—a majority of them in the pre-clinical stage. According to a recent report by Visiongain, the market for these drugs could grow to a value of $3.75 billion over the next three years.
RBCC and Amarantus plan to capitalize on this growth by commercializing a powerful new weapon in the fight against Parkinson's. The companies plan to work together to deliver NuroPro, a revolutionary new early-detection diagnostic blood test that could soon prove key to successfully treating Parkinson's and other neurological diseases. The PD application of this diagnostic has completed proof-of-concept and Phase I clinical validation studies.
For more information on Rainbow BioSciences, the biotech subsidiary of Rainbow Coral Corp., please visit www.rainbowbiosciences.com/investors.html.
About Rainbow BioSciences
Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.RainbowBioSciences.com]. For investment information and performance data on the company, please visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.
Rainbow Coral Corp.
Patrick Brown, 813-367-9511
President and CEO
KEYWORDS: United States North America Florida
The article RBCC Increases Focus on Parkinson's Disease originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.